Raphaëlle Leau, Pierre Duplouye, Virginie Huchet, Véronique Nerrière-Daguin, Bernard Martinet, Mélanie Néel, Martin Morin, Richard Danger, Cécile Braudeau, Régis Josien, Gilles Blancho, Fabienne Haspot
{"title":"正确刺激 CD28H 武器 NK 细胞对抗肿瘤细胞。","authors":"Raphaëlle Leau, Pierre Duplouye, Virginie Huchet, Véronique Nerrière-Daguin, Bernard Martinet, Mélanie Néel, Martin Morin, Richard Danger, Cécile Braudeau, Régis Josien, Gilles Blancho, Fabienne Haspot","doi":"10.1002/eji.202350901","DOIUrl":null,"url":null,"abstract":"<p>Tumor evasion has recently been associated with a novel member of the B7 family, HERV-H LTR-associating 2 (HHLA2), which is mostly overexpressed in PDL-1<sup>neg</sup> tumors. HHLA2 can either induce a costimulation signal when bound to CD28H or inhibit it by binding to KIR3DL3 on T- and NK cells. Given the broad distribution of CD28H expression on NK cells and its role, we compared two monoclonal antibodies targeting this novel NK-cell engager in this study. We show that targeting CD28H at a specific epitope not only strongly activates Ca<sup>2+</sup> flux but also results in NK-cell activation. CD28H-activated NK cells further display increased cytotoxic activity against hematopoietic cell lines and bypass HHLA2 and HLA-E inhibitory signals. Additionally, scRNA-seq analysis of clear cell renal cancer cells revealed that HHLA2<sup>+</sup> clear cell renal cancer cell tumors were infiltrated with CD28H<sup>+</sup> NK cells, which could be targeted by finely chosen anti-CD28H Abs.</p>","PeriodicalId":165,"journal":{"name":"European Journal of Immunology","volume":"54 11","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.202350901","citationCount":"0","resultStr":"{\"title\":\"Correct stimulation of CD28H arms NK cells against tumor cells\",\"authors\":\"Raphaëlle Leau, Pierre Duplouye, Virginie Huchet, Véronique Nerrière-Daguin, Bernard Martinet, Mélanie Néel, Martin Morin, Richard Danger, Cécile Braudeau, Régis Josien, Gilles Blancho, Fabienne Haspot\",\"doi\":\"10.1002/eji.202350901\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Tumor evasion has recently been associated with a novel member of the B7 family, HERV-H LTR-associating 2 (HHLA2), which is mostly overexpressed in PDL-1<sup>neg</sup> tumors. HHLA2 can either induce a costimulation signal when bound to CD28H or inhibit it by binding to KIR3DL3 on T- and NK cells. Given the broad distribution of CD28H expression on NK cells and its role, we compared two monoclonal antibodies targeting this novel NK-cell engager in this study. We show that targeting CD28H at a specific epitope not only strongly activates Ca<sup>2+</sup> flux but also results in NK-cell activation. CD28H-activated NK cells further display increased cytotoxic activity against hematopoietic cell lines and bypass HHLA2 and HLA-E inhibitory signals. Additionally, scRNA-seq analysis of clear cell renal cancer cells revealed that HHLA2<sup>+</sup> clear cell renal cancer cell tumors were infiltrated with CD28H<sup>+</sup> NK cells, which could be targeted by finely chosen anti-CD28H Abs.</p>\",\"PeriodicalId\":165,\"journal\":{\"name\":\"European Journal of Immunology\",\"volume\":\"54 11\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.202350901\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/eji.202350901\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/eji.202350901","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
肿瘤逃避最近与 B7 家族的一个新成员 HERV-H LTR-associating 2 (HHLA2) 有关,它在 PDL-1neg 肿瘤中大多过度表达。HHLA2 与 CD28H 结合可诱导成本刺激信号,或与 T- 和 NK 细胞上的 KIR3DL3 结合可抑制成本刺激信号。鉴于 CD28H 在 NK 细胞上的广泛分布及其作用,我们在本研究中比较了两种靶向这种新型 NK 细胞吞噬因子的单克隆抗体。我们发现,在特定表位上靶向 CD28H 不仅能强烈激活 Ca2+ 通量,还能导致 NK 细胞活化。CD28H 激活的 NK 细胞对造血细胞系的细胞毒活性进一步增强,并能绕过 HHLA2 和 HLA-E 抑制信号。此外,对透明细胞肾癌细胞进行的 scRNA-seq 分析表明,HHLA2+透明细胞肾癌细胞肿瘤被 CD28H+ NK 细胞浸润,而这些细胞可被精选的抗 CD28H Abs 靶向。
Correct stimulation of CD28H arms NK cells against tumor cells
Tumor evasion has recently been associated with a novel member of the B7 family, HERV-H LTR-associating 2 (HHLA2), which is mostly overexpressed in PDL-1neg tumors. HHLA2 can either induce a costimulation signal when bound to CD28H or inhibit it by binding to KIR3DL3 on T- and NK cells. Given the broad distribution of CD28H expression on NK cells and its role, we compared two monoclonal antibodies targeting this novel NK-cell engager in this study. We show that targeting CD28H at a specific epitope not only strongly activates Ca2+ flux but also results in NK-cell activation. CD28H-activated NK cells further display increased cytotoxic activity against hematopoietic cell lines and bypass HHLA2 and HLA-E inhibitory signals. Additionally, scRNA-seq analysis of clear cell renal cancer cells revealed that HHLA2+ clear cell renal cancer cell tumors were infiltrated with CD28H+ NK cells, which could be targeted by finely chosen anti-CD28H Abs.
期刊介绍:
The European Journal of Immunology (EJI) is an official journal of EFIS. Established in 1971, EJI continues to serve the needs of the global immunology community covering basic, translational and clinical research, ranging from adaptive and innate immunity through to vaccines and immunotherapy, cancer, autoimmunity, allergy and more. Mechanistic insights and thought-provoking immunological findings are of interest, as are studies using the latest omics technologies. We offer fast track review for competitive situations, including recently scooped papers, format free submission, transparent and fair peer review and more as detailed in our policies.